Your browser doesn't support javascript.
Defective Severe Acute Respiratory Syndrome Coronavirus 2 Immune Responses in an Immunocompromised Individual With Prolonged Viral Replication.
Gordon, Claire L; Smibert, Olivia C; Holmes, Natasha E; Chua, Kyra Y L; Rose, Morgan; Drewett, George; James, Fiona; Mouhtouris, Effie; Nguyen, Thi H O; Zhang, Wuji; Kedzierski, Lukasz; Rowntree, Louise C; Chua, Brendon Y; Caly, Leon; Catton, Mike G; Druce, Julian; Sait, Michelle; Seemann, Torsten; Sherry, Norelle L; Howden, Benjamin P; Kedzierska, Katherine; Kwong, Jason C; Trubiano, Jason A.
  • Gordon CL; Department of Infectious Diseases, Austin Hospital, Heidelberg, Victoria, Australia.
  • Smibert OC; Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
  • Holmes NE; Department of Infectious Diseases, Austin Hospital, Heidelberg, Victoria, Australia.
  • Chua KYL; Department of Infectious Diseases, Peter McCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Rose M; National Centre for Infections in Cancer, Peter McCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Drewett G; Department of Infectious Diseases, Austin Hospital, Heidelberg, Victoria, Australia.
  • James F; Data Analytics Research and Evaluation Centre, Austin Health and University of Melbourne, Heidelberg, Victoria, Australia.
  • Mouhtouris E; Department of Infectious Diseases, Austin Hospital, Heidelberg, Victoria, Australia.
  • Nguyen THO; Department of Infectious Diseases, Austin Hospital, Heidelberg, Victoria, Australia.
  • Zhang W; Department of Infectious Diseases, Austin Hospital, Heidelberg, Victoria, Australia.
  • Kedzierski L; Department of Infectious Diseases, Austin Hospital, Heidelberg, Victoria, Australia.
  • Rowntree LC; Department of Infectious Diseases, Austin Hospital, Heidelberg, Victoria, Australia.
  • Chua BY; Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
  • Caly L; Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
  • Catton MG; Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
  • Druce J; Faculty of Veterinary and Agricultural Sciences, University of Melbourne, Melbourne, Victoria, Australia.
  • Sait M; Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
  • Seemann T; Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
  • Sherry NL; Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
  • Howden BP; Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
  • Kedzierska K; Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
  • Kwong JC; Microbiological Diagnostic Unit Public Health Laboratory, Department of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
  • Trubiano JA; Microbiological Diagnostic Unit Public Health Laboratory, Department of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
Open Forum Infect Dis ; 8(9): ofab359, 2021 Sep.
Article in English | MEDLINE | ID: covidwho-1405048
ABSTRACT
We describe severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific immune responses in a patient with lymphoma and recent programmed death 1 (PD-1) inhibitor therapy with late onset of severe coronavirus disease 2019 disease and prolonged SARS-CoV-2 replication, in comparison to age-matched and immunocompromised controls. High levels of HLA-DR+/CD38+ activation, interleukin 6, and interleukin 18 in the absence of B cells and PD-1 expression was observed. SARS-CoV-2-specific antibody responses were absent and SARS-CoV-2-specific T cells were minimally detected. This case highlights challenges in managing immunocompromised hosts who may fail to mount effective virus-specific immune responses.
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Type of study: Observational study Language: English Journal: Open Forum Infect Dis Year: 2021 Document Type: Article Affiliation country: Ofid

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Type of study: Observational study Language: English Journal: Open Forum Infect Dis Year: 2021 Document Type: Article Affiliation country: Ofid